Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Depreciation and Depletion (2019 - 2025)

Historic Depreciation and Depletion for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $2.1 million.

  • Kymera Therapeutics' Depreciation and Depletion rose 500.0% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 1746.03%. This contributed to the annual value of $7.4 million for FY2024, which is 10555.56% up from last year.
  • Per Kymera Therapeutics' latest filing, its Depreciation and Depletion stood at $2.1 million for Q3 2025, which was up 500.0% from $1.7 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Depreciation and Depletion high stood at $2.4 million for Q4 2021, and its period low was $700.0 during Q3 2021.
  • For the 5-year period, Kymera Therapeutics' Depreciation and Depletion averaged around $1.2 million, with its median value being $900000.0 (2023).
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first plummeted by 9986.0% in 2021, then soared by 11418571.43% in 2022.
  • Over the past 5 years, Kymera Therapeutics' Depreciation and Depletion (Quarter) stood at $2.4 million in 2021, then crashed by 66.64% to $800000.0 in 2022, then rose by 12.5% to $900000.0 in 2023, then soared by 122.22% to $2.0 million in 2024, then increased by 5.0% to $2.1 million in 2025.
  • Its Depreciation and Depletion was $2.1 million in Q3 2025, compared to $1.7 million in Q2 2025 and $1.6 million in Q1 2025.